phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 7554R
英文名称phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)
中文名称磷酸化内皮细胞受体蛋白酪氨酸激酶础2+础3+础4抗体
别 名Eph receptor A2+A3+A4(phospho Y588 + Y596) ECK; EPH Receptor A2; EPH Receptor A3; EPH Receptor A4; EPHA2; EPHA3; EPHA4; Ephrin type A receptor 2; Ephrin type A receptor 3; Ephrin type A receptor 4; Epithelial cell kinase; ETK; ETK1; HEK; HEK4; HEK8; Receptor protein tyrosine kinase HEK8; SEK; TYRO4; Tyrosine protein kinase receptor SEK; Tyrosine protein kinase TYRO1; Tyrosine protein kinase TYRO4; Tyrosine-protein kinase receptor ECK; Tyrosine-protein kinase receptor ETK1.
说 明 书100ul
产物类型磷酸化抗体
研究领域心血管 细胞生物 神经生物学 信号转导 激酶和磷酸酶 细胞膜受体
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量105kDa
细胞定位细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human Eph receptor A2 around the phosphorylation site of Tyr588 + Tyr596:KT(p-Y)VD <Cytoplasmic>
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
Eph receptor A2 is the receptor for members of the ephrin-A family. It binds to ephrin-A1, -A3, -A4 and -A5. Eph receptor A3 is also a receptor for members of the ephrin-A family. It binds to ephrin-A2, -A3, -A4 and -A5 and is thought to play a role in lymphoid function. Eph receptor A4 is a receptor for members of the ephrin-A family. It binds to ephrin-A1, -A4 and -A5. It binds more poorly to ephrin-A2 and -A3. It may play a role in a signal transduction process involved in hindbrain pattern formation.
Function:
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.
Subunit:
Homodimer. Interacts with SLA. Interacts (phosphorylated form) with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); critical for the EFNA1-induced activation of RAC1 which stimulates cell migration. Interacts with ANKS1A. Interacts with INPPL1; regulates activated EPHA2 endocytosis and degradation. Interacts (inactivated form) with PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 and ELMO2; mediates ligand-independent activation of RAC1 which stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 and may regulate tight junctions. Interacts with ACP1.
Subcellular Location:
Cell membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane; Single-pass type I membrane protein. Cell projection, lamellipodium membrane; Single-pass type I membrane protein. Cell junction, focal adhesion. Note=Present at regions of cell-cell contacts but also at the leading edge of migrating cells.
Tissue Specificity:
Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g., skin, intestine, lung, and ovary.
Post-translational modifications:
Autophosphorylates. Phosphorylated on tyrosine upon binding and activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are required for binding VAV2 and VAV3 while phosphorylated residues Tyr-735 and Tyr-930 are required for binding PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which transduce downstream signaling to activate RAC1 GTPase and cell migration. Phosphorylated at Ser-897 by PKB; serum-induced phosphorylation which targets EPHA2 to the cell leading edge and stimulates cell migration. Phosphorylation by PKB is inhibited by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal regulatory loop. Dephosphorylated by ACP1.
Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the HSP90 chaperone and regulates the receptor stability and activity through proteasomal degradation. ANKS1A prevents ubiquitination and degradation.
DISEASE:
Genetic variations in EPHA2 are the cause of susceptibility to cataract cortical age-related type 2 (ARCC2) [MIM:613020]. A developmental punctate opacity common in the cortex and present in most lenses. The cataract is white or cerulean, increases in number with age, but rarely affects vision.
Defects in EPHA2 are the cause of cataract posterior polar type 1 (CTPP1) [MIM:116600]. A subcapsular opacity, usually disk-shaped, located at the back of the lens. It can have a marked effect on visual acuity.
Note=Overexpressed in several cancer types and promotes malignancy.
Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.
Contains 1 Eph LBD (Eph ligand-binding) domain.
Contains 2 fibronectin type-III domains.
Contains 1 protein kinase domain.
Contains 1 SAM (sterile alpha motif) domain.
SWISS:
P29317
Gene ID:
1969
phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-Eph receptor A2+A3+A4 (Tyr588 + Tyr596)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 RNF17 环指蛋白17抗体
合格 合格 TRIM7 糖原生成素相互作用蛋白抗体
合格 RNF87 环指蛋白87
合格 RNF3 环指蛋白3抗体
合格 合格 RNF6 环指蛋白6抗体
合格 RNF10 环指蛋白10抗体
合格 Repetin 中间丝相关蛋白抗体
合格 合格 VGLL2 转录辅助因子退变样蛋白2抗体
合格 VGLL3 转录辅助因子退变样蛋白3抗体
合格 合格 PTPH1 蛋白酪氨酸磷酸酶H1抗体
合格 合格 MLT5 睾丸特异性MLT5蛋白抗体
合格 CD101 CD101抗体
合格 合格 IGSF9 **球蛋白超家族成员9抗体
合格 IGSF11 大脑和睾丸特异性**球蛋白超家族成员11抗体
合格 IGSF12 **球蛋白超家族成员12抗体
合格 合格 IGSF21 **球蛋白超家族成员21抗体
合格 GDE3 促进成骨细胞分化因子/GDPD2抗体
合格 SERPINB11 丝氨酸蛋白酶抑制剂B11抗体
合格 SERPINB12 丝氨酸蛋白酶抑制剂B12抗体
合格 CST8 胱抑素8/半胱氨酸蛋白酶抑制剂8抗体
合格 C1orf149 1号染色体开放阅读框149抗体
合格 C1orf187/Draxin 1号染色体开放阅读框187抗体
合格 C1orf183 1号染色体开放阅读框183抗体
合格 RNF14 环指蛋白14抗体
合格 合格 RNF156 环指蛋白156抗体
合格 RNF35 环指蛋白35抗体
合格 RNF24 环指蛋白24抗体
合格 RNF25 环指蛋白25抗体
合格 RNF21 环指蛋白21抗体
合格 RNF123 环指蛋白123抗体
合格 RNF128 环指蛋白128抗体
合格 RNF133 环指蛋白133抗体
合格 RNF138 环指蛋白138抗体
合格 RNF113B 环指蛋白113B抗体
合格 合格 RNF150 环指蛋白150抗体
合格 RNF169 环指蛋白169抗体
合格 RNF170 环指蛋白170抗体
合格 合格 RNF186 环指蛋白186抗体
合格 phospho-IRF3 (Ser386) 磷酸化干扰素调节因子3抗体
合格 SLC47A1 溶质载体蛋白家族47成员A1抗体